Trademark: LIMINAL BIOSCIENCES 2120818
Word
LIMINAL BIOSCIENCES
ID
2120818
Trademark Type
Word
Status
Protected: Registered/protected
Application Date
16 April 2020
Registration Date
16 April 2020
Renewal Date
16 April 2030
Owner(s)
Service
FB Rice Pty Ltd
Goods and Services:
Class 5:
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, alzheimer's, cerebral palsy, parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, alzheimer's disease, parkinson's disease, huntington's disease and multiple sclerosis; anti-viral agents; antibiotics; antivirals; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, alzheimer's, huntington's disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), parkinson's disease, multiple sclerosis, myasthenia gravis.
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, alzheimer's, cerebral palsy, parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, alzheimer's disease, parkinson's disease, huntington's disease and multiple sclerosis; anti-viral agents; antibiotics; antivirals; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, alzheimer's, huntington's disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), parkinson's disease, multiple sclerosis, myasthenia gravis.
Class 42:
Development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; research on the subject of pharmaceuticals.
Development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; research on the subject of pharmaceuticals.